|Videos|May 14, 2020

Contagion Live News Network: Italian Doctors Report Kawasaki Syndrome in Pediatric COVID-19 Cases

A briefing on the day's top stories.

Hello and thank you for joining Contagion. I’m assistant editor Grant Gallagher, here with a review of our coverage on May 14, 2020.

A rare inflammatory disease typically affecting children 5 and under has been tentatively connected to the coronavirus. The Kawasaki Disease Link in Children, something that has been the subject of speculation for some time now, has had the first confirmatory evidence published. The reports come from hospitals in northern Italy.

We also featured part 1 of an interview with Dr.Adam Brufsky, a medical oncologist, who brings his outside expertise to discuss the potential role of hyperglycemia in severity of COVID-19. Dr Brufsky has contributed articles to several peer reviewed journals, working with experts native to the infectious disease field, and the theories he discusses in this multi-part interview could change the way we understand SARS-CoV-2.

In other news, the FDA Approved the first Umbilical Cord Stem Cell Trial for Severe COVID-19 Care. This randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

We also covered Adolescent Hepatitis C Novel Oral Therapies, which may allow more cost-effective treatment of HCV.

And lastly, Moderna’s messenger RNA Vaccine candidate mRNA-1273 has been granted Fast Track designation by the US FDA.

For more on all of these stories and other infectious disease news, visit contagionlive.com.


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.